Finding new ways to identify and treat cognitive problems caused by chemotherapy in cancer survivors.
Identification of novel biomarkers and therapeutic strategies in chemobrain.
This study is looking at how chemotherapy can affect thinking and memory in children who have survived cancer, and it aims to find ways to predict who might have these issues and develop new treatments to help them feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11125914 on NIH RePORTER |
What this research studies
This research focuses on understanding how chemotherapy can lead to cognitive impairment, known as chemotherapy-induced cognitive impairment (CICI), particularly in children who survive cancer. The team aims to identify biomarkers that can predict which patients are more susceptible to these cognitive issues and to develop new therapeutic strategies to mitigate these effects. By studying the role of a specific enzyme, PARP1, and its impact on neuronal health, the researchers hope to find effective treatments that can improve the quality of life for cancer survivors. The approach includes both identifying biological markers and testing new drugs that could help protect against cognitive decline.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults who have undergone chemotherapy for cancer and are experiencing cognitive difficulties.
Not a fit: Patients who have not undergone chemotherapy or those with cognitive impairments from non-cancer-related causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better identification and treatment options for cognitive impairments in cancer survivors, significantly improving their quality of life.
How similar studies have performed: Previous research has shown promise in identifying biomarkers and therapeutic strategies for cognitive impairments related to chemotherapy, suggesting that this approach could yield valuable insights.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Jang, Mi-Hyeon — Rutgers Biomedical and Health Sciences
- Study coordinator: Jang, Mi-Hyeon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.